WO2024199734 - FUSION COMPOUNDS AND USES THEREOF
National phase entry:
Publication Number
WO/2024/199734
Publication Date
03.10.2024
International Application No.
PCT/EP2024/025136
International Filing Date
27.03.2024
Title **
[English]
FUSION COMPOUNDS AND USES THEREOF
[French]
COMPOSÉS DE FUSION ET LEURS UTILISATIONS
Applicants **
NOVO NORDISK A/S
Novo Alle 1
2880 Bagsværd, DK
Inventors
ANDERSEN, Birgitte
Novo Alle 1
2880 Bagsværd, DK
TAGMOSE, Tina, Møller
Novo Alle 1
2880 Bagsværd, DK
Priority Data
23165485.6
30.03.2023
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1710 | |
| EPO | Filing, Examination | 6319 | |
| Japan | Filing | 531 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 3685 |
Total: 12820 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The invention relates to fusion proteins comprising a GLP-1 polypeptide and an FGF21 polypeptide separated by spacers. The invention also relates to fusion compounds comprising the fusion proteins and at least one substituent. The invention also relates to the pharmaceutical use of the fusion compounds.[French]
L'invention concerne des protéines de fusion comprenant un polypeptide GLP-1 et un polypeptide FGF21 séparés par des espaceurs. L'invention concerne également des composés de fusion comprenant les protéines de fusion et au moins un substituant. L'invention concerne également l'utilisation pharmaceutique des composés de fusion.